Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)

The Quick Take
– Week 48 Data from the Phase 3 SENTRY Trial Selected for Oral Presentation – – Data from the Phase 2 SENTRY-2 Trial Selected for Oral Presentation – NEWTON, Mass., Nov. 4, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm" or the "Company"), a commercial-stage...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
Risen Energy Energy Storage mantiene su estatus de Nivel 1 en BloombergNEF durante todo 2026
NINGHAI, China, 4 de noviembre de 2026 /PRNewswire/ -- Tenemos excelentes noticias. Risen Energy Energy Storage ha sido reconocida una vez más en la lista Tier…
Local
Could Democrats Federally Legalize Marijuana With Their New Senate And House Majorities?
Democrats won big in Tuesday’s midterm elections, retaking majorities in both the U.S. Senate and House of Representatives—a development that advocates say…
Business
Earnings call transcript: Nippon Sanso Q2 2026 revenue beats forecast, shares rise
Business
